Records 1-30 (of 131 Records) |
Query Trace: NHS[original query] |
---|
Digital measurement of SARS-CoV-2 transmission risk from 7 million contacts. Luca Ferretti et al. Nature 2023 12
From the abstract: "Here we analysed 7 million contacts notified by the NHS COVID-19 app6,7 in England and Wales to infer how app measurements translated to actual transmissions. Empirical metrics and statistical modelling showed a strong relation between app-computed risk scores and actual transmission probability. Longer exposures at greater distances had similar risk to shorter exposures at closer distances. The probability of transmission confirmed by a reported positive test increased initially linearly with duration of exposure (1.1% per hour) and continued increasing over several days. "
|
PCR testing of traced contacts for SARS-CoV-2 in England, January to July 2021. Nonnenmacher Toby, et al. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2023 0 0. (44) |
A Scoping Review of Digital Technologies Used in Monitoring COVID-19. Olanrewaju Zaid, et al. Studies in health technology and informatics 2023 0 0. 310-311 |
VIDIIA Hunter diagnostic platform: a low-cost, smartphone connected, artificial intelligence-assisted COVID-19 rapid diagnostics approved for medical use in the UK. Poirier Aurore C, et al. Frontiers in molecular biosciences 2023 0 0. 1144001 |
Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent. Pascall David J, et al. The Journal of infection 2023 0 0. |
Impact of SARS-CoV2 infection on mortality and hospitalization in nursing home residents during the "Omicron era". Bulgaresi Matteo, et al. Aging clinical and experimental research 2023 0 0. |
Drivers of SARS-CoV-2 testing behaviour: a modelling study using nationwide testing data in England. Kim Younjung, et al. Nature communications 2023 0 0. (1) 2148 |
Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study. Eyre David W, et al. The Lancet. Infectious diseases 2023 0 0. |
Combining viral genomics and clinical data to assess risk factors for severe COVID-19 (mortality, ICU admission, or intubation) amongst hospital patients in a large acute UK NHS hospital Trust. Foxley-Marrable Max, et al. PloS one 2023 0 0. (3) e0283447 |
Protocol for an OpenSAFELY cohort study collecting patient-reported outcome measures using the TPP Airmid smartphone application and linked big data to quantify the health and economic costs of long COVID (OpenPROMPT). Herrett Emily, et al. BMJ open 2023 0 0. (2) e071261 |
Epidemiological impacts of the NHS COVID-19 app in England and Wales throughout its first year M Kendall et al, Nat Comm, February 22, 2023
The NHS COVID-19 app was launched in England and Wales in September 2020, with a Bluetooth-based contact tracing functionality designed to reduce transmission of SARS-CoV-2. We show that user engagement and the app’s epidemiological impacts varied according to changing social and epidemic characteristics throughout the app’s first year. We describe the interaction and complementarity of manual and digital contact tracing approaches.
We estimate that the app’s contact tracing function alone averted about 1 million cases (sensitivity analysis 450,000–1,400,000) during its first year, corresponding to 44,000 hospital cases (SA 20,000–60,000) and 9,600 deaths (SA 4600–13,000).
|
Multiple pathways of SARS-CoV-2 nosocomial transmission uncovered by integrated genomic and epidemiological analyses during the second wave of the COVID-19 pandemic in the UK. Kate F Cook et al. Frontiers in cellular and infection microbiology 2023 2 1066390 |
Authentication of Covid-19 Vaccines Using Synchronous Fluorescence Spectroscopy. Assi Sulaf, et al. Journal of fluorescence 2023 0 0. |
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. Liu Zhigang, et al. The lancet. Gastroenterology & hepatology 2022 0 0. |
Performing under Pressure: Insights into the Diagnostic Testing Burden at a UK National Health Service Clinical Virology Laboratory during the SARS-CoV-2 Pandemic. Bird Paul William, et al. Viruses 2022 0 0. (10) |
COVID-19 Genomics UK (COG-UK) Consortium: Final Report. Marjanovic Sonja, et al. Rand health quarterly 2022 0 0. (4) 24 |
Public health impact of booster vaccination against COVID-19 in the UK during Delta variant dominance in autumn 2021. Mendes Diana, et al. Journal of medical economics 2022 0 0. (1) 1039-1050 |
EpiBeds: Data informed modelling of the COVID-19 hospital burden in England. Overton Christopher E, et al. PLoS computational biology 2022 0 0. (9) e1010406 |
A rapid RT-LAMP SARS-CoV-2 screening assay for collapsing asymptomatic COVID-19 transmission. Allsopp Rebecca C, et al. PloS one 2022 0 0. (9) e0273912 |
Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. Ward Isobel L, et al. BMJ (Clinical research ed.) 2022 0 0. e070695 |
Prediction of hospital-onset COVID-19 infections using dynamic networks of patient contact: an international retrospective cohort study. Myall Ashleigh, et al. The Lancet. Digital health 2022 0 0. (8) e573-e583 |
Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY. Hulme William J, et al. BMJ (Clinical research ed.) 2022 0 0. e068946 |
Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. Horne Elsie M F, et al. BMJ (Clinical research ed.) 2022 0 0. e071249 |
Development of a Mortality Prediction Model in Hospitalised SARS-CoV-2 Positive Patients Based on Routine Kidney Biomarkers. Boss Anna N, et al. International journal of molecular sciences 2022 0 0. (13) |
Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY. , et al. BMC medicine 2022 0 0. (1) 243 |
The effect of notification window length on the epidemiological impact of COVID-19 contact tracing mobile applications. Leng Trystan, et al. Communications medicine 2022 0 0. 74 |
The effect of notification window length on the epidemiological impact of COVID-19 contact tracing mobile applications T Leng et al, Communications Medicine, June 27, 2022
We use an epidemiological model of SARS-CoV-2 transmission that captures the profile of infection to consider the trade-off between notification window length and active app use. We focus on 5-day and 2-day windows, the notification windows of the NHS COVID-19 app in England and Wales before and after 2nd August 2021, respectively. Our analyses show that at the same level of active app use, 5-day windows result in larger reductions in transmission than 2-day windows. However, short notification windows can be more effective at reducing transmission if they are associated with higher levels of active app use and adherence to isolation upon notification.
|
COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records. Thygesen Johan H, et al. The Lancet. Digital health 2022 0 0. |
Machine learning generalizability across healthcare settings: insights from multi-site COVID-19 screening. Yang Jenny, et al. NPJ digital medicine 2022 0 0. (1) 69 |
COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records JH Thygesen et al, The Lancet Digital Health, June 8, 2022
Updatable estimates of COVID-19 onset, progression, and trajectories underpin pandemic mitigation efforts. To identify and characterise disease trajectories, we aimed to define and validate ten COVID-19 phenotypes from nationwide linked electronic health records (EHR) using an extensible framework.
In this cohort study, we used eight linked National Health Service (NHS) datasets for people in England alive on Jan 23, 2020. Data on COVID-19 testing, vaccination, primary and secondary care records, and death registrations were collected until Nov 30, 2021. We defined ten COVID-19 phenotypes reflecting clinically relevant stages of disease severity and encompassing five categories: positive SARS-CoV-2 test, primary care diagnosis, hospital admission, ventilation modality (four phenotypes), and death (three phenotypes).
|
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 19, 2024
- Content source: